PI3K inhibitor

PI3K is an enzyme central to cell growth and proliferation. A mutation in the gene that makes this enzyme (PIK3CA) can cause it to be overactive, leading to breast cancer. PI3K inhibitors target this mutation. There are two currently approved by the FDA to treat advanced or metastatic cancers that are hormone receptor–positive/HER2-negative: alpelisib (Piqray®) and inavolisib (Itovebi™). Both are oral medications given with hormone therapy.